Logo

SCYX

SCYNEXIS, Inc.

SCYX

SCYNEXIS, Inc. • NASDAQ
$0.69 ▲ 1.75% (+0.01)
Market Cap $28.95 M
52w High $1.49
52w Low $0.56
Dividend Yield 0%
P/E -1.35
Volume 231.43K
Outstanding Shares 41.96M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $334K ▼ $8.739M ▼ $-8.591M ▼ -2.572K% ▼ $-0.17 ▼ $-186K ▼
Q2-2025 $1.364M ▲ $10.925M ▲ $-6.885M ▼ -504.765% ▲ $-0.14 ▼ $2.676M ▼
Q1-2025 $257K ▼ $8.867M ▼ $-5.391M ▼ -2.098K% ▼ $-0.11 ▲ $3.392M ▲
Q4-2024 $977K ▲ $9.03M ▼ $-4.433M ▼ -453.736% ▼ $-0.12 ▼ $-3.735M ▼
Q3-2024 $660K $10.98M $-2.808M -425.455% $-0.058 $-2.99M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $38.008M ▼ $51.071M ▼ $14.641M ▼ $36.43M ▼
Q2-2025 $44.785M ▲ $60.694M ▼ $16.227M ▼ $44.467M ▼
Q1-2025 $40.607M ▼ $67.915M ▼ $17.383M ▼ $50.532M ▼
Q4-2024 $59.3M ▼ $90.643M ▼ $35.566M ▼ $55.077M ▼
Q3-2024 $68.828M $99.038M $40.509M $58.529M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-8.591M ▼ $-8.724M ▼ $12.417M ▲ $29K ▲ $3.722M ▼ $-8.724M ▼
Q2-2025 $-6.885M ▼ $-7.495M ▼ $11.273M ▼ $0 ▲ $3.778M ▲ $-7.495M ▼
Q1-2025 $-5.391M ▼ $-7.465M ▲ $12.44M ▲ $-14.084M ▼ $-9.109M ▲ $-7.465M ▲
Q4-2024 $-4.433M ▼ $-9.907M ▼ $-2.617M ▼ $-155K ▼ $-12.679M ▼ $-9.907M ▼
Q3-2024 $-2.808M $765K $1.941M $31K $2.737M $765K

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
License and Service
License and Service
 $0 ▲$0 ▲$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement SCYNEXIS’s income statement shows a classic early‑stage biotech pattern: mostly small or no recurring product revenue, paired with ongoing operating losses. One recent year stands out with a sizable profit, likely driven by a licensing or upfront partnership payment rather than from steady drug sales. Outside of that unusual year, the business has been loss‑making, reflecting heavy spending on research, clinical trials, and overhead. Profitability is therefore volatile and highly dependent on deal activity and milestones, not yet on a mature commercial franchise. That means past profits may not be a reliable guide to future performance unless the company can convert its scientific progress and partnerships into more stable revenue streams over time.

Balance Sheet

Balance Sheet The balance sheet is modest in size, consistent with a small biotech focused on a narrow therapeutic area. Assets and cash have moved up and down over the last few years, with a meaningful boost around the time of the large partnership event and some drawdown afterward as funds were used to run the business. Debt exists but appears contained relative to the overall scale of the company, and shareholder equity has moved from very thin levels to a healthier, though still small, cushion. Overall, the balance sheet provides some support but does not look deep enough to fund many years of aggressive development without additional capital, milestones, or partnerships.

Cash Flow

Cash Flow Cash flow follows the same story as earnings: one strong year where operating cash turned positive due to partnership funding, surrounded by years of negative cash flow. Day‑to‑day operations and R&D spending typically consume cash, as is common for a company at this stage. Capital expenditures are minimal, which means most cash outlay goes directly into people, trials, and development rather than buildings or equipment. The key question for the future is whether incoming partnership payments, potential milestones, or new financing can offset ongoing cash burn from research and overhead.

Competitive Edge

Competitive Edge SCYNEXIS occupies a specialized niche in antifungal treatments, targeting serious infections and resistant strains where existing drugs are often inadequate. Its main product, based on the novel “fungerp” class, offers a distinct mechanism and the flexibility of both oral and intravenous forms, which can be attractive in hospital and outpatient settings. The company’s patent estate and first‑in‑class status provide a real, though not unassailable, competitive moat. At the same time, it competes indirectly with very large pharmaceutical firms that dominate the antifungal market. SCYNEXIS’s strategic partnership with GSK is a critical part of its competitive position, giving it commercial reach and development support that it likely could not build on its own—but also creating dependency on a partner’s priorities and execution.

Innovation and R&D

Innovation and R&D Innovation is the core of SCYNEXIS’s story. Its lead molecule, ibrexafungerp, represents a new class of antifungals that can address drug‑resistant infections and work in challenging environments in the body. This scientific differentiation is meaningful in a field where resistance is a growing concern and treatment options are limited. Beyond the first drug, the company is advancing SCY‑247, a next‑generation candidate that early data suggest may be more efficient and better tolerated. SCYNEXIS also has earlier‑stage assets built on the same technology platform. The upside is a focused, coherent R&D strategy with clear expertise; the risk is concentration, since much of the company’s future hinges on the success of a single drug class and the outcome of ongoing clinical and regulatory milestones.

Summary

Overall, SCYNEXIS looks like a classic high‑innovation, high‑risk biotech: scientifically differentiated, financially lean, and heavily reliant on partnerships. The income statement and cash flows show that sustainable, product‑driven revenue has not yet been established, and one‑off deals have had an outsized impact on reported results. On the positive side, the company has carved out a defensible niche in antifungal therapy, backed by patents, first‑in‑class status, and supportive clinical data. The relationship with GSK can amplify its strengths but also adds reliance on a single major partner. Future outcomes will likely hinge on: successful commercialization of existing products by GSK, progress of next‑generation candidates like SCY‑247, access to funding to support ongoing development, and navigating regulatory and clinical risks typical of this sector.

NEWS

November 19, 2025 · 7:00 AM UTC

SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSK

Read more

November 5, 2025 · 4:20 PM UTC

SCYNEXIS Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Read more

October 15, 2025 · 8:00 AM UTC

SCYNEXIS and GSK Resolve Their Disagreement Related to the Restart of the Phase 3 MARIO Study

Read more

September 4, 2025 · 8:30 AM UTC

SCYNEXIS Announces Multiple Presentations Highlighting Data from its Second-Generation Fungerp, SCY-247, at the 12th Congress on Trends in Medical Mycology (TIMM-12)

Read more